BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26634708)

  • 1. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K
    Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
    Zayac AS; Landsburg DJ; Hughes ME; Bock AM; Nowakowski GS; Ayers EC; Girton M; Hu M; Beckman AK; Li S; Medeiros LJ; Chang JE; Stepanovic A; Kurt H; Sandoval-Sus J; Ansari-Lari MA; Kothari SK; Kress A; Xu ML; Torka P; Sundaram S; Smith SD; Naresh KN; Karimi YH; Epperla N; Bond DA; Farooq U; Saad M; Evens AM; Pandya K; Naik SG; Kamdar M; Haverkos B; Karmali R; Oh TS; Vose JM; Nutsch H; Rubinstein PG; Chaudhry A; Olszewski AJ
    Blood Adv; 2023 Nov; 7(21):6381-6394. PubMed ID: 37171397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
    Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS; Blum KA; Kahl BS; Friedberg JW; Baizer L; Little RF; Maloney DG; Sehn LH; Williams ME; Wilson WH; Leonard JP; Smith SM
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27986884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma.
    de Jonge AV; Bult JAA; Karssing DFE; Nijland M; Chamuleau MED; Brink M
    Blood Cancer J; 2024 Jan; 14(1):2. PubMed ID: 38177113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
    Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
    Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients.
    Gagnon MF; Bruehl FK; Sill DR; Meyer RG; Greipp PT; Hoppman NL; Xu X; Baughn LB; Peterson JF; McPhail ED; Ketterling RP; King RL
    J Hematop; 2024 Jun; 17(2):51-61. PubMed ID: 38561469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
    Zeremski V; McPhail ED; Habermann TM; Schieppati F; Gebauer N; Vassilakopoulos TP; Mougiakakos D
    Hematol Oncol; 2023 Oct; 41(4):776-780. PubMed ID: 36945194
    [No Abstract]   [Full Text] [Related]  

  • 9. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified.
    Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
    Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An increase in
    Schieppati F; Balzarini P; Fisogni S; Re A; Pagani C; Bianchetti N; Micheli L; Passi A; Ferrari S; Maifredi A; Bottelli C; Leopaldo R; Pellegrini V; Facchetti F; Rossi G; Tucci A
    Haematologica; 2020 May; 105(5):1369-1378. PubMed ID: 31399522
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary cardiac large B cell lymphoma.
    Arun Kumar S; Mishra R; Malempati SC; Bindal P
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38151268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
    Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
    Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.
    Khelfa Y; Lebowicz Y
    J Investig Med High Impact Case Rep; 2016; 4(2):2324709616642592. PubMed ID: 27115017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Gagnon MF; Meyer RG; Weaver EJ; Wood AJ; Dupuy DA; Menachery SJ; Shi M; Baughn LB; Ketterling RP; Peterson JF
    Lab Med; 2024 Mar; ():. PubMed ID: 38522075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
    Rodriguez-Pinilla SM; Dojcinov S; Dotlic S; Gibson SE; Hartmann S; Klimkowska M; Sabattini E; Tousseyn TA; de Jong D; Hsi ED
    Virchows Arch; 2024 Jan; 484(1):15-29. PubMed ID: 37530792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.
    Gao G; Xue Q; He J; Wu M; Jiang Y; Li Q; Zhang Y; Shi W
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111125. PubMed ID: 37907047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
    Hilton LK; Collinge BJ; Ben-Neriah S; Alduaij W; Shaalan H; Weng A; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami GG; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
    Blood; 2024 May; ():. PubMed ID: 38701426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered pathways and targeted therapy in double hit lymphoma.
    Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
    J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Liu Z; Li S; Guo W; Wang Y; Wang M; Bai O
    Biomed Res Int; 2017; 2017():1967648. PubMed ID: 29209623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.